Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease

Desnick, 2001, Chapter XVI: Lysosomal disorders Park, 2008, Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect, Clin. Exp. Pharmacol. Physiol., 35, 1156, 10.1111/j.1440-1681.2008.04984.x Shu, 2007, Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice, J. Biol. Chem., 282, 20960, 10.1074/jbc.M702436200 Lee, 2003, A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease, Glycobiology, 13, 305, 10.1093/glycob/cwg034 Kornfeld, 1982, Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes, Ciba Found. Symp., 92, 138 Neufeld, 1980, The uptake of enzymes into lysosomes: An overview, Birth Defects Orig. Artic. Ser., 16, 77 Beck, 2009, Agalsidase alfa for the treatment of Fabry disease: New data on clinical efficacy and safety, Expert Opin. Biol. Ther., 9, 255, 10.1517/14712590802658428 Desnick, 2004, Enzyme replacement therapy for Fabry disease: Lessons from two alpha-galactosidase A orphan products and one FDA approval, Expert Opin. Biol. Ther., 4, 1167, 10.1517/14712598.4.7.1167 Mehta, 2008, Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta, Mol. Genet. Metab., 95, 114, 10.1016/j.ymgme.2008.07.002 Murray, 2007, Cellular and tissue distribution of intravenously administered agalsidase alfa, Mol. Genet. Metab., 90, 307, 10.1016/j.ymgme.2006.11.008 Koskenvuo, 2008, Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters, J. Inherit. Metab. Dis., 31, 432, 10.1007/s10545-008-0848-3 Schiffmann, 2005, Fabry's disease: An important risk factor for stroke, Lancet, 366, 1754, 10.1016/S0140-6736(05)67636-2 Cardone, 2008, Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts, Pathogenetics, 1, 6, 10.1186/1755-8417-1-6 Dhami, 2004, Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: Implications for Niemann–Pick disease enzyme replacement therapy, J. Biol. Chem., 279, 1526, 10.1074/jbc.M309465200 Linthorst, 2004, Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta, Kidney Int., 66, 1589, 10.1111/j.1523-1755.2004.00924.x Ohashi, 2008, Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease, Mol. Genet. Metab., 94, 313, 10.1016/j.ymgme.2008.03.008 Marlin, 1987, Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1), Cell, 51, 813, 10.1016/0092-8674(87)90104-8 DeGraba, 2000, Profile of endothelial and leukocyte activation in Fabry patients, Ann. Neurol., 47, 229, 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T Shen, 2008, Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells, Mol. Genet. Metab., 95, 163, 10.1016/j.ymgme.2008.06.016 Bloemen, 1995, Adhesion molecules: A new target for immunoliposome-mediated drug delivery, FEBS Lett., 357, 140, 10.1016/0014-5793(94)01350-A Chittasupho, 2009, ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells, Eur. J. Pharm. Sci., 37, 141, 10.1016/j.ejps.2009.02.008 Finikova, 2008, Oxygen microscopy by two-photon-excited phosphorescence, Chemphyschem, 9, 1673, 10.1002/cphc.200800296 Garnacho, 2008, Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers, J. Pharmacol. Exp. Ther., 325, 400, 10.1124/jpet.107.133298 Murciano, 2003, ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface, Blood, 101, 3977, 10.1182/blood-2002-09-2853 Muro, 2005, ICAM-1 recycling in endothelial cells: A novel pathway for sustained intracellular delivery and prolonged effects of drugs, Blood, 105, 650, 10.1182/blood-2004-05-1714 Muro, 2008, Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers, Mol. Ther., 16, 1450, 10.1038/mt.2008.127 Muro, 2006, Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis, Mol. Ther., 13, 135, 10.1016/j.ymthe.2005.07.687 Rossin, 2008, In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium, J. Nucl. Med., 49, 103, 10.2967/jnumed.107.045302 Sakhalkar, 2003, Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo, Proc. Natl Acad. Sci. USA, 100, 15895, 10.1073/pnas.2631433100 Villanueva, 1998, Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells, Circulation, 98, 1, 10.1161/01.CIR.98.1.1 Weiner, 2001, Early detection of oleic acid-induced lung injury in rats using (111)In-labeled anti-rat intercellular adhesion molecule-1, J. Nucl. Med., 42, 1109 Aird, 2007, Phenotypic heterogeneity of the endothelium II: Representative vascular beds, Circ. Res., 100, 174, 10.1161/01.RES.0000255690.03436.ae Viemann, 2006, TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells, J. Leukoc. Biol., 80, 174, 10.1189/jlb.0905530 Muro, 2003, A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1, J. Cell Sci., 116, 1599, 10.1242/jcs.00367 Gehr, 1978, The normal human lung: Ultrastructure and morphometric estimation of diffusion capacity, Respir. Physiol., 32, 121, 10.1016/0034-5687(78)90104-4 Higenbottam, 1998, Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture, Chest, 114, 72S, 10.1378/chest.114.1_Supplement.72S Jaffe, 1987, Cell biology of endothelial cells, Hum. Pathol., 18, 234, 10.1016/S0046-8177(87)80005-9 Muro, 2006, Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1, J. Pharmacol. Exp. Ther., 317, 1161, 10.1124/jpet.105.098970 Legler, 1986, Synthesis of 5-amino-5-deoxy-D-galactopyranose and 1, 5-dideoxy-1, 5-imino-D-galactitol, and their inhibition of alpha- and beta-D-galactosidases, Carbohydr. Res., 155, 119, 10.1016/S0008-6215(00)90138-1 Muro, 2010, New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2, 189, 10.1002/wnan.73 Mumtaz, 1994, Enhanced intracellular stability and efficacy of PEG modified dextranase in the treatment of a model storage disorder, Biochim. Biophys. Acta, 1199, 175, 10.1016/0304-4165(94)90113-9 Stefano, 2009, In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins, J. Control. Release, 135, 113, 10.1016/j.jconrel.2008.12.006 Steger, 1977, Enzyme therapy VI: Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes, Biochim. Biophys. Acta, 464, 530, 10.1016/0005-2736(77)90028-1 Ansari, 1997, Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and Batten disease cells, J. Neurosci. Res., 47, 341, 10.1002/(SICI)1097-4547(19970201)47:3<341::AID-JNR12>3.0.CO;2-4 Weissmann, 1975, A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells, Proc. Natl Acad. Sci. USA, 72, 88, 10.1073/pnas.72.1.88 El-Sayed, 2005, Smart polymeric carriers for enhanced intracellular delivery of therapeutic macromolecules, Expert Opin. Biol. Ther., 5, 23, 10.1517/14712598.5.1.23 Langer, 1998, Drug delivery and targeting, Nature, 392, 5 Panyam, 2003, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv. Drug Deliv. Rev., 55, 329, 10.1016/S0169-409X(02)00228-4 Torchilin, 2006, Multifunctional nanocarriers, Adv. Drug Deliv. Rev., 58, 1532, 10.1016/j.addr.2006.09.009 De Vocht, 2009, Assessment of stability, toxicity and immunogenicity of new polymeric nanoreactors for use in enzyme replacement therapy of MNGIE, J. Control. Release, 137, 246, 10.1016/j.jconrel.2009.03.020 Sahay, 2010, Endocytosis of nanomedicines, J. Control. Release, 145, 182, 10.1016/j.jconrel.2010.01.036 Torchilin, 2008, Intracellular delivery of protein and peptide therapeutics, Drug Discovery Today Technol., 5, e95, 10.1016/j.ddtec.2009.01.002 Mundargi, 2008, Nano/Micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives, J. Control. Release, 125, 193, 10.1016/j.jconrel.2007.09.013